Innoviva, Inc. (INVA)

Market Cap	1.56B
Revenue (ttm)	388.52M
Net Income (ttm)	127.34M
Shares Out	74.77M
EPS (ttm)	1.52
PE Ratio	13.73
Forward PE	12.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	715,500
Open	20.74
Previous Close	20.58
Day's Range	20.28 - 21.10
52-Week Range	16.52 - 22.00
Beta	0.49
Analysts	Buy
Price Target	36.60 (+74.95%)
Earnings Date	Nov 5, 2025

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2004
• Employees: 127
• Stock Exchange: NASDAQ
• Ticker Symbol: INVA
• Website: https://www.inva.com

Financial Performance

In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.

Analyst Summary

According to 5 analysts, the average rating for INVA stock is "Buy." The 12-month stock price target is $36.6, which is an increase of 74.95% from the latest price.

Price Target

$36.6

(74.95% upside)

Analyst Consensus: Buy